Belsomra (Suvorexant) Cost in New Hampshire: Prices, Insurance, and Savings in 2026

The direct answer

Suvorexant, sold under the brand name Belsomra, is an FDA-approved prescription medication for insomnia. There is no FDA-approved generic suvorexant tablet as of this writing, which keeps the branded product's list price higher than older generic sleep aids such as zolpidem or eszopiclone. Actual out-of-pocket cost in New Hampshire depends on insurance type, pharmacy, and manufacturer or pharmacy discount programs, and these figures shift often enough that a specific dollar amount quoted today may not hold in a few months. Anyone budgeting for Belsomra in New Hampshire should get a real-time quote from their own pharmacy and insurer rather than relying on a published average.

Why we are not publishing specific price figures here

The source material behind an earlier version of this page cited a $340 list price and an $85 average NH cash-pay price, along with specific copay ranges ($40 to $75), a 340B discount range (25% to 50% below WAC), and step-therapy timelines. None of these figures could be verified against a primary source (an FDA label does not set retail or cash pricing, and no New Hampshire-specific pricing survey was available). Drug pricing, especially brand-name pricing subject to rebates and PBM contracts, changes frequently and varies by pharmacy. Rather than repeat unverified numbers as if they were current facts, this page describes the mechanisms that drive cost and points readers to where they can get a current, accurate quote.

If your editorial team has access to a verified 2026 New Hampshire pricing survey or a signed data-sharing agreement with a pricing aggregator, those specific figures can be added back with a citation and a date.

What Belsomra is and how it works

Suvorexant blocks orexin receptors involved in wakefulness, a different mechanism than the GABA-A modulators (zolpidem, eszopiclone, trazodone) that have historically been first-line for insomnia. The FDA approved suvorexant in 2014 for insomnia involving difficulty with sleep onset, sleep maintenance, or both. A randomized controlled trial in patients with insomnia reported that suvorexant improved wake after sleep onset (WASO) and subjective total sleep time compared with placebo over the study period (Herring et al., 2014). That trial supports suvorexant's efficacy for the FDA-approved indication; it does not address cost, New Hampshire-specific access, or comparative effectiveness against lemborexant, which has not been directly studied head-to-head with suvorexant in the material reviewed here.

New Hampshire Medicaid: what to verify before assuming coverage

Whether New Hampshire Medicaid currently covers Belsomra, and under what prior authorization criteria, is a state-specific and date-specific fact that changes as the preferred drug list (PDL) is updated. The source material asserted non-coverage but did not link to the actual NH Medicaid PDL or fee schedule, so that claim is not verified here. Patients and prescribers should check the current NH Medicaid PDL directly or call NH Medicaid member services before assuming either coverage or denial.

In general, state Medicaid programs tend to favor low-cost generic insomnia agents (such as generic zolpidem or trazodone) over single-source branded drugs like suvorexant, and prior authorization is a common mechanism when a branded drug is non-preferred. That is a reasonable expectation based on how PDLs typically work, not a confirmed New Hampshire-specific fact for 2026.

Insurance coverage: what varies by plan

Commercial insurance formulary placement for Belsomra (which tier, what copay, whether prior authorization or step therapy applies) is set independently by each insurer and pharmacy benefit manager, and changes at least annually. The source material named specific insurers (Anthem, Cigna, Harvard Pilgrim, Ambetter) and specific copay ranges without a verifiable source; those specifics are removed here pending direct confirmation from each plan's current formulary document.

What is established rather than plan-specific: Medicare Part D plans generally do cover branded insomnia drugs like Belsomra as part of their formularies, subject to tier placement and prior authorization rules set by each plan sponsor, and the 2025 implementation of the Inflation Reduction Act's annual out-of-pocket cap for Part D applies to all covered Part D drugs, not to Belsomra specifically (CMS). Beneficiaries should check their specific Part D plan's formulary for Belsomra's tier and any prior authorization requirement.

Self-funded employer plans in New Hampshire set their own formularies through their PBM (Express Scripts, CVS Caremark, OptumRx, or others). The only reliable way to know coverage and cost under one of these plans is to call the number on the pharmacy benefit card or check the plan's online formulary.

Manufacturer and pharmacy discount programs

Manufacturer copay savings cards for branded drugs like Belsomra typically apply only to patients with commercial insurance, because federal anti-kickback rules bar their use with Medicare, Medicaid, or Tricare. That structural rule is well established across the pharmaceutical industry. The specific dollar cap, eligibility criteria, and whether a copay accumulator program (used by some insurers) will prevent the card's value from counting toward a deductible are plan-specific and change over time; patients should confirm current terms directly on the manufacturer's official Belsomra program page and with their pharmacy at the point of sale.

Pharmacy discount programs (GoodRx, SingleCare, and similar services) publish live pricing that can be checked at the time of fill; a printed average price becomes stale quickly and should not be treated as guaranteed.

Federally qualified health centers (FQHCs) that participate in the 340B Drug Pricing Program may offer reduced pricing to patients seen at those centers, but exact 340B pricing is not publicly disclosed and varies by drug and contract, so no specific discount percentage is stated here.

Compounded suvorexant: a genuine legal caution

Suvorexant remains under patent protection, which raises a real access question that a generic sleep aid does not: a 503A compounding pharmacy compounding a patient-specific prescription for a patented, non-scarce drug operates in a legally different position than compounding a drug that is in shortage or lacks a commercial equivalent. Compounding of a patented drug that is commercially available and not in shortage can raise both patent-law and FDA compounding-policy concerns that a generic insomnia drug would not raise. Patients considering a compounded version of a patented drug should ask their prescriber and the compounding pharmacy directly about the legal basis for that specific compound, and should understand that compounded drugs do not go through FDA's bioequivalence review process, so potency and absorption may differ from the FDA-approved tablet.

Telehealth prescribing in New Hampshire

Suvorexant is a Schedule IV controlled substance under the DEA's scheduling framework, referenced generally on the FDA's site for drug scheduling and labeling information (FDA). Since 2023, the DEA has maintained a framework allowing qualifying telehealth prescribing of Schedule III-V controlled substances following an audio-video evaluation, subject to state licensure requirements. Whether a specific New Hampshire telehealth platform can prescribe Belsomra to a given patient depends on the prescriber holding a valid New Hampshire license and completing an appropriate clinical evaluation; this is a prescribing decision made case by case, not a blanket guarantee across every telehealth service.

Comparing suvorexant to other insomnia treatments on cost and clinical fit

Older, generic insomnia medications (zolpidem, eszopiclone, trazodone used off-label) are generally far less expensive than any branded DORA, because they have generic competition and suvorexant currently does not. That price gap is a structural fact of patent status, not a New Hampshire-specific phenomenon.

The clinical case for choosing suvorexant over a cheaper generic typically arises when a patient has not responded to or cannot tolerate a GABA-A modulator, has a history of complex sleep behaviors (sleepwalking, sleep-driving) associated with the FDA's boxed warning for zolpidem, eszopiclone, and zaleplon, or has a comorbid substance use disorder where a non-GABA mechanism may be preferred by the prescriber. The FDA's boxed warning on complex sleep behaviors applies to the specific drugs named in that warning; it does not extend automatically to the DORA class, though prescribers should still discuss next-day sedation and other suvorexant-specific risks with patients according to FDA prescribing information for suvorexant.

Lemborexant (Dayvigo) is the other FDA-approved DORA and is generally similarly priced to Belsomra as a branded drug. Direct head-to-head trial data comparing suvorexant and lemborexant were not available in the material reviewed for this page, so any claim of superiority between them should be treated as unestablished until a specific comparative trial is cited.

Evidence boundary: what is established, what is not

Established: Suvorexant is FDA-approved for insomnia and works through orexin receptor antagonism, a distinct mechanism from GABA-A modulators. A randomized trial supports efficacy for sleep onset and maintenance outcomes at the studied doses. Suvorexant is a Schedule IV controlled substance, and federal telehealth rules permit controlled-substance prescribing via audio-video evaluation, subject to state licensing. Medicare Part D generally covers branded drugs on some tier, subject to plan rules, and the IRA out-of-pocket cap applies across Part D.

Plausible but not documented here: That New Hampshire cash-pay pricing sits meaningfully below list price (true of most branded drugs generally, given rebates and discount programs, but no verified New Hampshire-specific figure was available). That specific NH commercial insurers place suvorexant on a particular formulary tier.

Not established in the source material reviewed: Any specific dollar price for Belsomra in New Hampshire in 2026, New Hampshire Medicaid's exact current coverage decision and PDL status for suvorexant, specific copay ranges by named insurer, and any comparative claim that suvorexant outperforms lemborexant.

Verification checklist: stable facts vs. facts that expire

Use this checklist to separate what a reader can trust as durable from what must be re-checked at the point of care or purchase.

Stable facts (federal/clinical, unlikely to change soon):

• Suvorexant is FDA-approved for insomnia involving sleep onset and/or maintenance difficulty (approved 2014).
• Suvorexant is a Schedule IV controlled substance under DEA scheduling.
• Suvorexant's mechanism (orexin receptor antagonism) differs from GABA-A modulators like zolpidem.
• The FDA boxed warning on complex sleep behaviors names zolpidem, eszopiclone, and zaleplon specifically.
• Manufacturer copay cards for branded drugs generally exclude Medicare, Medicaid, and Tricare beneficiaries by federal rule.

Facts that expire and must be re-verified before quoting to a patient:

• Belsomra's current list price (WAC) and any published cash-pay average for New Hampshire pharmacies.
• New Hampshire Medicaid's current preferred drug list status for suvorexant and any prior authorization criteria.
• Specific commercial insurers' formulary tier and copay for Belsomra in New Hampshire this plan year.
• Whether a specific insurer applies a copay accumulator program that blocks manufacturer card value from counting toward the deductible.
• Current terms, dollar caps, and eligibility rules for the manufacturer's savings card program.
• Current 340B pricing availability at a specific New Hampshire FQHC.
• Whether a specific telehealth platform currently has a New Hampshire-licensed prescriber accepting new patients for controlled-substance evaluations.
• Whether a generic suvorexant tablet has since received FDA approval, which would materially change pricing.

Before publishing or advising a patient based on any item in the second list, confirm it against the primary source (NH Medicaid PDL, the specific insurer's current formulary document, or the pharmacy's point-of-sale quote) dated within the current quarter.

When to seek care rather than rely on this page

This page addresses cost and access, not individualized treatment decisions. Anyone with new or worsening insomnia, especially alongside symptoms like chest pain, shortness of breath, mood changes, or thoughts of self-harm, should contact a clinician or emergency services rather than trying to resolve the issue through a pricing comparison. Suvorexant carries risks including next-day impairment and, rarely, complex sleep behaviors; dosing and suitability should be determined by a prescriber familiar with the patient's full medical history, not by this article.